Novo Nordisk AI Stock Analysis
Novo Nordisk (0TDD) AI Stock Analysis
Novo Nordisk
(LSE:0TDD)
No summary available
Novo Nordisk (0TDD) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $183.39B
- Dividend Yield
- 4.42%
- Average Volume (3M)
- 113.48K
- Price to Earnings (P/E)
- 11.2
- Beta (1Y)
- 0.86
- Revenue Growth
- 11.16%
- EPS Growth
- 15.62%
- Country
- UK
- Employees
- 68,794
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Novo Nordisk Business Overview & Revenue Model
Company Description
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Af...
Novo Nordisk Earnings Call Summary
The call was broadly positive, supported by Q3 sales and operating profit growth, improving patient volumes, strong uptake of the Wegovy and Ozempic pills, substantial clinical and pipeline progress, an accelerated international rollout, and raised 2026 guidance. However, management also highlighted near-flat full-year guidance, U.S. and international pricing pressure, loss-of-exclusivity impacts, China headwinds, payer resistance, and normalization of early Wegovy pill uptake. Highlights significantly outweighed the stated challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Novo’s 2030 ambition is to deliver mid-single-digit compounded annual sales growth in line with our industry peers from 2026 to 2030; for 2026, adjusted sales growth is now expected to be -2% to +2% at CER, adjusted operating profit growth is now expected to be from - 2% to + 2% at constant exchange rates, and free cash flow is now expected between DKK 60 billion and DKK 70 billion. By first half of 2027, Wegovy pill is expected to be available in more than 20 markets; Frehemgo is planned to roll out globally during 2027, pending approval; denecimig is expected to launch in European countries by the turn of this year, with a broader rollout in 2027, and in the U.S. in the first half of 2027, pending regulatory decision. AMAZE 9 is expected to read out in 2028, Amylin 355 is expected to read out in the second half of 2027 in around 170 patients, ACSL5 inhibitor phase I results are anticipated in the second half of 2027, RENEW 1 and 2 phase III results are anticipated around mid-2027, and phase I/II results for both tri-agonists are anticipated in the first half of 2027.
Novo Nordisk Risk Analysis
Novo Nordisk disclosed 17 risk factors in its most recent earnings report. Novo Nordisk reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksNovo Nordisk Peers Comparison
Overall Rating
SNY83Outperform
LLY81Outperform
AMGN75Outperform
NVS72Outperform
MRK64Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | $116.45B | 25.31 | 5.84% | 5.00% | 23.68% | -30.90% | |
| 81Outperform | $1.35T | 46.54 | 83.65% | 0.48% | 45.51% | 50.48% | |
| 75Outperform | $250.07B | 26.65 | 85.59% | 2.15% | 8.60% | 33.48% | |
| 72Outperform | $295.59B | 31.08 | 24.24% | 2.96% | 1.64% | -28.72% | |
| 64Neutral | $356.13B | 147.39 | 5.29% | 2.35% | 5.21% | -86.88% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0TDD | Novo Nordisk | 41.07 | -4.62 | -10.11% | |
| AMGN | Amgen Inc | 462.32 | 127.62 | 38.13% | |
| LLY | Eli Lilly And Company | 1431.67 | 407.82 | 39.83% | |
| MRK | Merck & Company | 144.46 | 50.78 | 54.21% | |
| NVS | Novartis AG | 160.20 | 34.65 | 27.60% | |
| SNY | Sanofi SA | 48.39 | -0.33 | -0.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
